CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody
- PMID: 1360879
- PMCID: PMC1554591
- DOI: 10.1111/j.1365-2249.1992.tb05855.x
CD4-independent binding of HIV-1 to the B lymphocyte receptor CR2 (CD21) in the presence of complement and antibody
Abstract
Complement and antibody contribute to infection-enhancement and possible expanded cellular tropism of HIV-1 in vitro through a process requiring complement receptors. Until now, however, the ability of HIV-1 to bind complement receptors has not been documented or characterized. We investigated whether antibody and complement permitted HIV-1 to bind to the B lymphocyte receptor, CR2 (CD21), in an effort to learn more about infection-enhancement, and also because CR2 can mediate B cell proliferation and antigen localization in lymphoid organs in other systems. HIV-1 incubated with antibody and fresh human serum as a source of complement bound approximately 10-fold greater to cells expressing CR2 than to HIV-1-permissive cells lacking this receptor. A similar effect was observed using cells which expressed CR2 but no CD4. This binding was minimal in heat-inactivated and C3-deficient sera, and was significantly reduced by the anti-CR2 MoAb, OKB7, but not by the anti-CD4 MoAb, OKT4a. Thus, complement and antibody acted in concert to facilitate the binding of HIV-1 to CR2 independently of CD4. CD4-independent binding of HIV-1 to CR2 was not sufficient to produce infection in Raji-3 cells. Titres of antibodies mediating CR2 binding correlated with antibody titres as measured by immunofluorescence (P < 0.01) and infection-enhancement (P < 0.05) but were discordant with titres of neutralizing antibodies, a result consistent with the utilization of CR2 for enhanced infection of cells. The ability of complement and antibody to facilitate the binding of HIV-1 to CR2 in the absence of CD4 provides new insights into mechanisms of HIV-1-induced immunopathogenesis and infection-enhancement.
Similar articles
-
Complement-mediated binding of naturally glycosylated and glycosylation-modified human immunodeficiency virus type 1 to human CR2 (CD21).J Virol. 1993 May;67(5):2699-706. doi: 10.1128/JVI.67.5.2699-2706.1993. J Virol. 1993. PMID: 8474169 Free PMC article.
-
Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV.Scand J Immunol. 1993 Aug;38(2):183-9. doi: 10.1111/j.1365-3083.1993.tb01711.x. Scand J Immunol. 1993. PMID: 8346417
-
Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion.J Exp Med. 1991 May 1;173(5):1151-8. doi: 10.1084/jem.173.5.1151. J Exp Med. 1991. PMID: 1827139 Free PMC article.
-
Deficiencies of human C3 complement receptors type 1 (CR1, CD35) and type 2 (CR2, CD21).Immunodefic Rev. 1990;2(1):17-41. Immunodefic Rev. 1990. PMID: 2164822 Review.
-
Complement receptor 2, natural antibodies and innate immunity: Inter-relationships in B cell selection and activation.Mol Immunol. 2007 Jan;44(1-3):64-72. doi: 10.1016/j.molimm.2006.07.003. Epub 2006 Jul 28. Mol Immunol. 2007. PMID: 16876864 Review.
Cited by
-
Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.J Clin Microbiol. 2002 Jun;40(6):2141-6. doi: 10.1128/JCM.40.6.2141-2146.2002. J Clin Microbiol. 2002. PMID: 12037078 Free PMC article.
-
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.PLoS One. 2017 Jul 5;12(7):e0180720. doi: 10.1371/journal.pone.0180720. eCollection 2017. PLoS One. 2017. PMID: 28678869 Free PMC article.
-
Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection.J Virol. 1995 Apr;69(4):2393-400. doi: 10.1128/JVI.69.4.2393-2400.1995. J Virol. 1995. PMID: 7884885 Free PMC article.
-
An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys.J Virol. 1996 May;70(5):3198-206. doi: 10.1128/JVI.70.5.3198-3206.1996. J Virol. 1996. PMID: 8627800 Free PMC article.
-
Structural biology of complement receptors.Front Immunol. 2023 Sep 11;14:1239146. doi: 10.3389/fimmu.2023.1239146. eCollection 2023. Front Immunol. 2023. PMID: 37753090 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous